XML 44 R29.htm IDEA: XBRL DOCUMENT
v3.25.3

Note 11 - Segment Information (Tables) | 6 Months Ended
--- | ---
Sep. 30, 2025
Notes Tables |
Schedule of Segment Reporting Information, by Segment [Table Text Block] |
Three months ended September 30, 2025 |  | Sterilization and Disinfection Control |  |  | Biopharmaceutical Development |  |  | Calibration Solutions |  |  | Clinical Genomics |  |  | Total |
Revenues (a): |  | $ | 22,107 |  |  | $ | 13,920 |  |  | $ | 13,570 |  |  | $ | 11,140 |  |  | $ | 60,737 |
Less |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Depreciation in cost of revenues |  |  | 461 |  |  |  | 66 |  |  |  | 112 |  |  |  | 152 |  |  |  | 791 |
Amortization in cost of revenues |  |  | 140 |  |  |  | 375 |  |  |  | - |  |  |  | 192 |  |  |  | 707 |
Other cost of revenues (b) |  |  | 6,636 |  |  |  | 5,350 |  |  |  | 5,223 |  |  |  | 4,699 |  |  |  | 21,908 |
Total segment cost of revenues |  |  | 7,237 |  |  |  | 5,791 |  |  |  | 5,335 |  |  |  | 5,043 |  |  |  | 23,406 |
Gross Profit (c) |  | $ | 14,870 |  |  | $ | 8,129 |  |  | $ | 8,235 |  |  | $ | 6,097 |  |  | $ | 37,331 |
Reconciling items: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 32,607 |
Operating income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 4,724 |
Nonoperating expense, net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 2,725 |
Earnings before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 1,999 |
Three months ended September 30, 2024 |  | Sterilization and Disinfection Control |  |  | Biopharmaceutical Development |  |  | Calibration Solutions |  |  | Clinical Genomics |  |  | Total |
Revenues (a): |  | $ | 22,205 |  |  | $ | 11,867 |  |  | $ | 12,262 |  |  | $ | 11,499 |  |  | $ | 57,833 |
Less |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Depreciation in cost of revenues |  |  | 374 |  |  |  | 40 |  |  |  | 207 |  |  |  | 283 |  |  |  | 904 |
Amortization in cost of revenues |  |  | 134 |  |  |  | 346 |  |  |  | - |  |  |  | 192 |  |  |  | 672 |
Non-cash GKE inventory step-up amortization |  |  | 454 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 454 |
Other cost of revenues (b) |  |  | 6,071 |  |  |  | 4,314 |  |  |  | 4,845 |  |  |  | 5,118 |  |  |  | 20,348 |
Total segment cost of revenues |  |  | 7,033 |  |  |  | 4,700 |  |  |  | 5,052 |  |  |  | 5,593 |  |  |  | 22,378 |
Gross Profit (c) |  | $ | 15,172 |  |  | $ | 7,167 |  |  | $ | 7,210 |  |  | $ | 5,906 |  |  | $ | 35,455 |
Reconciling items: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 31,947 |
Operating income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 3,508 |
Nonoperating (income), net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (304 | )
Earnings before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 3,812 |
Six months ended September 30, 2025 |  | Sterilization and Disinfection Control |  |  | Biopharmaceutical Development |  |  | Calibration Solutions |  |  | Clinical Genomics |  |  | Total |
Revenues (a): |  | $ | 47,517 |  |  | $ | 25,406 |  |  | $ | 25,920 |  |  | $ | 21,437 |  |  | $ | 120,280 |
Less |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Depreciation in cost of revenues |  |  | 911 |  |  |  | 155 |  |  |  | 217 |  |  |  | 318 |  |  |  | 1,601 |
Amortization in cost of revenues |  |  | 279 |  |  |  | 747 |  |  |  | - |  |  |  | 383 |  |  |  | 1,409 |
Other cost of revenues (b) |  |  | 13,291 |  |  |  | 10,069 |  |  |  | 10,426 |  |  |  | 9,214 |  |  |  | 43,000 |
Total segment cost of revenues |  |  | 14,481 |  |  |  | 10,971 |  |  |  | 10,643 |  |  |  | 9,915 |  |  |  | 46,010 |
Gross Profit (c) |  | $ | 33,036 |  |  | $ | 14,435 |  |  | $ | 15,277 |  |  | $ | 11,522 |  |  | $ | 74,270 |
Reconciling items: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 66,482 |
Operating income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 7,788 |
Nonoperating (income), net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | (1,223 | )
Earnings before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 9,011 |
Six months ended September 30, 2024 |  | Sterilization and Disinfection Control |  |  | Biopharmaceutical Development |  |  | Calibration Solutions |  |  | Clinical Genomics |  |  | Total |
Revenues (a): |  | $ | 45,162 |  |  | $ | 23,875 |  |  | $ | 24,063 |  |  | $ | 22,903 |  |  | $ | 116,003 |
Less |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Depreciation in cost of revenues |  |  | 793 |  |  |  | 86 |  |  |  | 392 |  |  |  | 495 |  |  |  | 1,766 |
Amortization in cost of revenues |  |  | 245 |  |  |  | 691 |  |  |  | - |  |  |  | 383 |  |  |  | 1,319 |
Non-cash GKE inventory step-up amortization |  |  | 1,232 |  |  |  | - |  |  |  | - |  |  |  | - |  |  |  | 1,232 |
Other cost of revenues (b) |  |  | 12,162 |  |  |  | 7,972 |  |  |  | 9,219 |  |  |  | 9,629 |  |  |  | 38,982 |
Total segment cost of revenues |  |  | 14,432 |  |  |  | 8,749 |  |  |  | 9,611 |  |  |  | 10,507 |  |  |  | 43,299 |
Gross Profit (c) |  | $ | 30,730 |  |  | $ | 15,126 |  |  | $ | 14,452 |  |  | $ | 12,396 |  |  | $ | 72,704 |
Reconciling items: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Operating expense |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 63,616 |
Operating income |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 9,088 |
Nonoperating expense, net |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | 1,371 |
Earnings before income taxes |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ | 7,717 |
Schedule of Segment Reporting Information, by Inventory Segment [Table Text Block] |
|  | September 30, |  |  | March 31, |
|  | 2025 |  |  | 2025 |
Sterilization and Disinfection Control |  | $ | 6,771 |  |  | $ | 5,545 |
Biopharmaceutical Development |  |  | 5,715 |  |  |  | 4,934 |
Calibration Solutions |  |  | 6,150 |  |  |  | 5,110 |
Clinical Genomics |  |  | 9,103 |  |  |  | 9,776 |
Total inventories |  | $ | 27,739 |  |  | $ | 25,365 |

X
- Definition A table disclosing the inventory totals for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment inventory reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment inventory. + References No definition available. + Details
Name: | mlab_ScheduleOfSegmentReportingInformationByInventorySegmentTableTextBlock
Namespace Prefix: | mlab_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details
Name: | us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_TableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration